Table 2.
(a–b) Predictive factors for response to second-line cytotoxic chemotherapy for HGSOC recurrence in the exploratory (2a) and validation cohort (2b). The endpoint of therapy response is classified as either complete or partial response after completed chemotherapy.
|
2a. Parameters
Exploratory Cohort |
Response to Second-Line Chemotherapy | |||
| Univariate Analysis | Multivariable Analysis | |||
| p-Value | OR (95% CI) | p-Value | OR (95% CI) | |
| Log growth rate constant >−3.32 | <0.001 | 2.57 (1.60–4.12) | 0.003 | 5.19 (1.73–15.58) |
| Therapy-free interval >6 months | 0.005 | 1.73 (1.29–2.31) | 0.453 | 1.95 (0.34–11.17) |
| Age at time of therapy >60 years | 0.03 | 1.35 (1.04–1.74) | 0.006 | 5.32 (1.63–17.38) |
| Platinum-based therapy yes/no | <0.001 | 5.39 (2.92–9.95) | <0.001 | 16.06 (4.48–53.29) |
| FIGO stage (2014) > FIGO IIIc | 0.055 | 1.69 (0.86–3.34) | - | - |
|
2b. Parameters
Validation Cohort |
Response to Second-Line Chemotherapy | |||
| Univariate Analysis | Multivariable Analysis | |||
| p-Value | OR (95% CI) | p-Value | OR (95% CI) | |
| Log growth rate constant >−3.32 | 0.008 | 1.60 (1.10–2.33) | 0.03 | 3.67 (1.13–11.86) |
| Therapy-free interval >6 months | 0.025 | 1.81 (0.95–3.47) | 0.661 | 1.48 (0.26–8.46) |
| Age at time of therapy >60 years | 0.03 | 7.58 (1.11–51.66) | 0.056 | 10.15 (0.94–109.25) |
| Platinum-based therapy yes/no | <0.001 | 2.65 (1.51–4.65) | 0.016 | 5.79 (1.40–24.05) |
| FIGO stage (2014) > FIGO IIIc | 0.048 | 1.68 (0.89–3.18) | - | - |
CI: Confidence interval, FIGO: International Federation of Gynecology and Obstetrics, OR: Odds ratio.